{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004186","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.585372+00:00","generated_at":"2026-05-18T17:11:17.701260+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M","bullets":["Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.","Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.","BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.","Sale includes European team; BioCryst saves at least $50M in annual operating expenses.","European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004186","json":"https://secwatch.observer/filing/0001171843-25-004186.json","markdown":"https://secwatch.observer/filing/0001171843-25-004186.md","text":"https://secwatch.observer/filing/0001171843-25-004186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/0001171843-25-004186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/f8k_062725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:11:17.701260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}